Skip to main content
OpenTrials
Completed

NCT Number: NCT05075187

Epidemiological Study in FRONtoTemporal Dementia

An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Frontotemporal Dementia Brain Diseases Central Nervous System Diseases Dementia Frontotemporal Lobar Degeneration Mental Disorders Metabolic Diseases Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Nutritional and Metabolic Diseases Proteostasis Deficiencies TDP-43 Proteinopathies

Age range

25 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

AZ Damiaan, Ostend, West Flanders, Belgium

Loading trial locations.

About this study

Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian
  • The participant is aged between 25 to 85 years
  • The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD

Treatment and study plan

Genetic Screening

Diagnostic Test

Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.

Primary outcomes

  1. To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants

    Time frame: 15 months

Sponsors and collaborators

Lead sponsor

CENTOGENE GmbH Rostock

Industry

Registry information

Acronym: EFRONT

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Oct 12, 2021
Registry last updated
Apr 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.